Breast cancer affects thousands of individuals in Brazil and Mexico, and is managed with premium-priced agents, chemotherapy, and hormone therapy. In Mexico, coverage of treatment varies across the…
Non-small-cell lung cancer (NSCLC) affects thousands of individuals in Brazil and Mexico, and it is managed with premium-priced targeted agents and chemotherapy. In both countries, public coverage…
In an era when healthcare payers are demanding more value for the money they spend on health services and pharmaceuticals, managed care organizations increasingly have focused on meeting nationally…
In recent years, biosimilars of epoetin alfa and filgrastim have been approved and launched in major markets. Uptake of these products among oncologists is increasing, driven by payers and…
Nephrologists and endocrinologists in Europe have had the opportunity to use biosimilar erythropoiesis-stimulating agents (ESAs) and human growth hormone (hGH), respectively, for several years, but…
Biologics prescribed by rheumatologists and gastroenterologists are among the most commercially successful biopharmaceutical products in the world. These biologics are a prime target for biosimilar…
Gaining physician confidence is critical to securing a meaningful position in developed markets; therefore, understanding their concerns about biosimilar products should be an important part of…
How payers choose to adopt and promote biosimilars will be highly impactful in determining the future commercial opportunity for biosimilars in the United States and across Europe. We conducted…
Developing a biosimilar requires considerable investment and expertise. In order to maximize potential commercial return, biosimilar developers must adopt clear and effective strategies that…
Latest update: Global Biosimilars Pipeline updated on 31 July 2015 The biosimilars market is not all about the United States, Europe, and Japan. Although these developed markets account for 75% of…
European oncologists have had high exposure to biosimilars compared with other European specialists owing to the availability of epoetin alfa and filgrastim biosimilars. Although no biosimilars are…
Nephrologists and endocrinologists in Europe have had the opportunity to use biosimilar erythropoiesis-stimulating agents (ESAs) and human growth hormone (hGH), respectively, for several years, but…
With biosimilar infliximab approved in Europe and filed for approval in the United States, rheumatologists and gastroenterologists will soon have the opportunity to prescribe biosimilars to their…
The fledgling biosimilars industry is full of uncertainties and nuances that differ by country, therapeutic specialty, and molecule. Securing a positive return on lengthy biosimilar development…
Payers will be instrumental in determining the future commercial opportunity for biosimilars in the United States and across Europe. We conducted primary market research with surveyed MCO pharmacy…